2
RESEARCH METHODOLOGY
33
5
MARKET OVERVIEW
AI-driven pathology revolutionizes diagnostics with personalized medicine, despite high costs and data challenges.
55
5.2.1.1
DEVELOPMENT OF CNNS AND ADVANCED AI MODELS
5.2.1.2
INTEGRATION OF AI INTO MULTIPLEX IMAGING
5.2.1.3
INCREASING CASES OF MISDIAGNOSES IN PATIENTS
5.2.1.4
BENEFITS OF AI-AUGMENTED TELEPATHOLOGY
5.2.1.5
ADVANCEMENTS IN DEEP LEARNING & IMAGE PROCESSING
5.2.2.1
HIGH COST OF DIGITAL PATHOLOGY SYSTEMS
5.2.2.2
LIMITED AI EXPERTISE AND VARIED REGULATORY GUIDELINES FOR MEDICAL SOFTWARE
5.2.2.3
INADEQUATE INTEROPERABILITY ISSUES WITH LEGACY SYSTEMS
5.2.3.1
INCREASING DEMAND FOR PERSONALIZED MEDICINES
5.2.3.2
INTEGRATION OF MULTI-OMICS DATA
5.2.3.3
PREDICTIVE ANALYTICS FOR DISEASE PROGRESSION
5.2.4.1
INSUFFICIENT DATA FOR AI ALGORITHMS
5.2.4.2
DATA PRIVACY AND ETHICAL CONCERNS
5.2.4.3
CHALLENGES ASSOCIATED WITH INTERPRETABILITY OF AI MODELS
5.3
TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4.1
EVOLUTION OF AI IN PATHOLOGY
5.7.1.1
MACHINE LEARNING (ML) AND ARTIFICIAL INTELLIGENCE (AI)
5.7.2
COMPLEMENTARY TECHNOLOGIES
5.7.3
ADJACENT TECHNOLOGIES
5.8.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8.2
REGULATIONS, BY REGION
5.9.1
AVERAGE SELLING PRICE TREND, BY REGION
5.9.2
INDICATIVE PRICING ANALYSIS, BY OFFERING
5.10
PORTER’S FIVE FORCES ANALYSIS
5.10.1
THREAT FROM NEW ENTRANTS
5.10.2
THREAT FROM SUBSTITUTES
5.10.3
BARGAINING POWER OF SUPPLIERS
5.10.4
BARGAINING POWER OF BUYERS
5.10.5
INTENSITY OF COMPETITIVE RIVALRY
5.11.1
PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
5.11.2
JURISDICTION AND TOP APPLICANT ANALYSIS
5.12
KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.13.1
UNMET NEEDS OF END USERS
5.13.2
END USER EXPECTATIONS
5.14
KEY CONFERENCES AND EVENTS, 2025–2026
5.15.1
CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES
5.15.2
CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS
5.15.3
CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES
5.16
INVESTMENT & FUNDING SCENARIO
5.18
IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
5.18.2
AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY
5.18.2.1
ACCELERATED BIOMARKER DISCOVERY AND CLINICAL TRIAL OPTIMIZATION
5.18.3
IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.18.3.1
DRUG DISCOVERY & DEVELOPMENT MARKET
5.18.3.2
MEDICAL IMAGING & DIAGNOSTICS MARKET
5.18.4
USER READINESS AND IMPACT ASSESSMENT
5.18.4.2
IMPACT ASSESSMENT
5.20.3
PRICE IMPACT ANALYSIS
5.20.4
IMPACT ON COUNTRY/REGION
5.20.5
IMPACT ON END USE INDUSTRIES
6
AI IN PATHOLOGY MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 9 Data Tables
101
6.2.1
INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
6.3
NICHE POINT SOLUTIONS
6.3.1
GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
6.4.1
RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET
6.5.1
HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET
6.6.1
NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH
6.7.1
IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
6.8.1
NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH
7
AI IN PATHOLOGY MARKET, BY NEURAL NETWORK
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
112
7.2
CONVOLUTIONAL NEURAL NETWORKS (CNNS)
7.2.1
FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
7.3
GENERATIVE ADVERSARIAL NETWORKS (GANS)
7.3.1
NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
7.4
RECURRENT NEURAL NETWORKS (RNNS)
7.4.1
NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET
7.5
OTHER NEURAL NETWORKS
8
AI IN PATHOLOGY MARKET, BY FUNCTION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 9 Data Tables
119
8.2.1
DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
8.3.1
RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
8.4.1
OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
8.5.1
EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND
8.6.1
GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET
8.7.1
PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
8.8
AUTOMATED REPORT GENERATION
8.8.1
INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
8.9
QUALITY ASSURANCE TOOLS
8.9.1
RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH
9
AI IN PATHOLOGY MARKET, BY USE CASE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 13 Data Tables
129
9.2.1
TARGET IDENTIFICATION & SELECTION
9.2.1.1
ANALYSIS OF MOLECULAR AND HISTOLOGICAL DATA FOR BIOMARKER DISCOVERY TO FUEL MARKET
9.2.2.1
INCREASING DEMAND FOR PRECISION MEDICINES TO DRIVE MARKET
9.2.3
HIT IDENTIFICATION & PRIORITIZATION
9.2.3.1
GROWING REQUIREMENT FOR RAPID ANALYSIS AND COST EFFICIENCY TO FUEL UPTAKE
9.2.4
HIT-TO-LEAD IDENTIFICATION
9.2.4.1
ADVANCEMENTS IN ML TO SUPPORT MARKET GROWTH
9.2.5.1
GROWING FOCUS ON THERAPEUTIC EFFICACY TO PROPEL MARKET
9.2.6
CANDIDATE SELECTION & VALIDATION
9.2.6.1
CRITICAL REQUIREMENT FOR REGULATORY APPROVALS TO DRIVE MARKET
9.3
DISEASE DIAGNOSIS & PROGNOSIS
9.3.1
INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
9.4.1
STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
9.5.1
UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH
10
AI IN PATHOLOGY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
143
10.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1
GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
10.3
HOSPITALS & REFERENCE LABORATORIES
10.3.1
INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH
10.4
ACADEMIC & RESEARCH INSTITUTES
10.4.1
GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND
11
AI IN PATHOLOGY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 12 Countries | 117 Data Tables.
148
11.2.1
MACROECONOMIC OUTLOOK
11.2.2.1
HIGH HEALTHCARE EXPENDITURE AND IMPROVEMENTS IN CLOUD COMPUTING PLATFORMS TO PROPEL MARKET
11.2.3.1
INCREASING ADOPTION OF DEEP LEARNING FOR ADVANCED HEALTHCARE DIAGNOSTICS TO DRIVE MARKET
11.3.1
MACROECONOMIC OUTLOOK
11.3.2.1
INCREASED FOCUS ON DRUG DISCOVERY AND DEVELOPMENT TO BOOST DEMAND
11.3.3.1
AVAILABILITY OF FUNDING FOR AI INITIATIVES TO FUEL UPTAKE
11.3.4.1
INCREASING ADOPTION OF BIG DATA IN HEALTHCARE COMPUTING TO FUEL UPTAKE
11.3.5.1
DIGITAL TRANSFORMATION AND INNOVATION IN HEALTHCARE TO SUPPORT MARKET GROWTH
11.3.6.1
INCREASED WORKFORCE SHORTAGE TO FUEL MARKET
11.4.1
MACROECONOMIC OUTLOOK
11.4.2.1
RISING CASES OF INFECTIOUS AND CHRONIC DISEASES TO FUEL DEMAND
11.4.3.1
ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
11.4.4.1
GROWING FOCUS ON HEALTHCARE DIGITIZATION TO BOOST DEMAND
11.4.5
REST OF ASIA PACIFIC
11.5.1
MACROECONOMIC OUTLOOK
11.5.2.1
STRATEGIC INVESTMENTS FOR AI ADOPTION TO SUPPORT MARKET GROWTH
11.5.3.1
GROWTH IN PHARMACEUTICAL R&D TO DRIVE MARKET
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
MACROECONOMIC OUTLOOK
11.6.2.1
INCREASING INVESTMENTS FOR EXPANSION OF TECHNOLOGICAL EXPERTISE TO SUPPORT GROWTH
11.6.3
REST OF MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Discover strategic moves and market dominance in AI pathology through key player analysis and financial metrics.
220
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
12.3
REVENUE ANALYSIS, 2020−2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
OFFERING FOOTPRINT
12.5.5.3
USE CASE FOOTPRINT
12.5.5.4
END USER FOOTPRINT
12.5.5.5
REGION FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.5
COMPETITIVE BENCHMARKING
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.8
BRAND/PRODUCT COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT/SERVICE LAUNCHES & APPROVALS
12.9.3
OTHER DEVELOPMENTS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
242
13.1.1
KONINKLIJKE PHILIPS N.V.
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS/SERVICES OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.2
F. HOFFMANN-LA ROCHE LTD.
13.1.4
AKOYA BIOSCIENCES, INC.
13.1.5
AIFORIA TECHNOLOGIES PLC
13.1.8
IBEX MEDICAL ANALYTICS LTD.
13.1.20
TEMPUS LABS, INC.
13.2.1
KONFOONG BIOINFORMATION TECH CO., LTD.
13.2.2
DOMORE DIAGNOSTICS AS
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
TABLE 1
EXCHANGE RATES, 2021–2024
TABLE 2
ROLE OF PLAYERS IN MARKET ECOSYSTEM
TABLE 3
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4
US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 5
US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 6
CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 7
EUROPE: CLASSIFICATION OF IVD DEVICES
TABLE 8
JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
TABLE 9
CHINA: CLASSIFICATION OF MEDICAL DEVICES
TABLE 10
INDICATIVE PRICING ANALYSIS, BY OFFERING
TABLE 11
IMPACT OF PORTER’S FORCES
TABLE 12
JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET
TABLE 13
KEY PATENTS IN AI IN PATHOLOGY MARKET
TABLE 14
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 15
KEY BUYING CRITERIA, BY END USER
TABLE 16
UNMET NEEDS OF END USERS
TABLE 17
AI IN PATHOLOGY MARKET: END USER EXPECTATIONS
TABLE 18
LIST OF CONFERENCES AND EVENTS, 2025–2026
TABLE 19
IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD THOUSAND)
TABLE 20
EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD MILLION)
TABLE 21
RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 22
TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS
TABLE 23
EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT
TABLE 24
AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 25
AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 26
AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 27
AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 28
AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023–2030 (USD MILLION)
TABLE 29
AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 30
AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 31
AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 32
AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 33
AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 34
AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 35
AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 36
AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 37
AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 38
AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 39
AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 40
AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 41
AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 42
AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 43
AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 44
AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 45
AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 46
AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 47
AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 48
DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
TABLE 49
AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2023–2030 (USD MILLION)
TABLE 50
AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 51
AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 52
AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 53
AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 54
AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 55
AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 56
AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 57
AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 58
AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 59
AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 60
AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 61
AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 62
AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 63
AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 64
AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 67
NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 68
NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 69
NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 70
NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 71
US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 72
US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 73
US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 74
US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 75
US: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 76
CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 77
CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 78
CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 79
CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 80
CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 81
EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 82
EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 83
EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 84
EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 85
EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 86
EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 87
UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 88
UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 89
UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 90
UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 91
UK: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 92
GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 93
GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 94
GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 95
GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 96
GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 97
FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 98
FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 99
FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 100
FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 101
FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 102
ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 103
ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 104
ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 105
ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 106
ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 107
SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 108
SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 109
SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 110
SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 111
SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 112
REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 113
REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 114
REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 115
REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 116
REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 117
ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 118
ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 119
ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 120
ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 121
ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 122
ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 123
CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 124
CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 125
CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 126
CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 127
CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 128
JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 129
JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 130
JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 131
JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 132
JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 133
JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 134
INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 135
INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 136
INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 137
INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 138
INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 139
REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 140
REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 141
REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 142
REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 143
REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 144
LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
TABLE 145
LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 146
LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 147
LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 148
LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 149
LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 150
BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 151
BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 152
BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 153
BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 154
BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 155
MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 156
MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 157
MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 158
MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 159
MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 160
REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 161
REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 162
REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 163
REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 164
REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 165
MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 166
MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 167
MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 168
MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 169
MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 170
MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 171
GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 172
GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 173
GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 174
GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 175
GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 176
REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 177
REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION)
TABLE 178
REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION)
TABLE 179
REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION)
TABLE 180
REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 181
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
TABLE 182
AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
TABLE 183
OFFERING FOOTPRINT
TABLE 184
USE CASE FOOTPRINT
TABLE 185
END USER FOOTPRINT
TABLE 186
REGION FOOTPRINT
TABLE 187
AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 188
AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 189
AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 190
AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–APRIL 2025
TABLE 191
AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021– APRIL 2025
TABLE 192
KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
TABLE 193
KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
TABLE 194
KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–APRIL 2025
TABLE 195
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 196
F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
TABLE 197
F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−MARCH 2025
TABLE 198
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−MARCH 2025
TABLE 199
HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 200
HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
TABLE 201
HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025
TABLE 202
AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
TABLE 203
AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
TABLE 204
AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021−APRIL 2025
TABLE 205
AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 206
AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
TABLE 207
AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−APRIL 2025
TABLE 208
INDICA LABS INC.: COMPANY OVERVIEW
TABLE 209
INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
TABLE 210
INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025
TABLE 211
INDICA LABS INC.: DEALS, JANUARY 2021−APRIL 2025
TABLE 212
INDICA LABS INC.: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 213
OPTRASCAN: COMPANY OVERVIEW
TABLE 214
OPTRASCAN: PRODUCTS/SERVICES OFFERED
TABLE 215
OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 216
IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
TABLE 217
IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
TABLE 218
IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 219
IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–APRIL 2025
TABLE 220
MINDPEAK GMBH: COMPANY OVERVIEW
TABLE 221
MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
TABLE 222
MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 223
MINDPEAK GMBH: DEALS, JANUARY 2021–APRIL 2025
TABLE 224
MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 225
TRIBUN HEALTH: COMPANY OVERVIEW
TABLE 226
TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
TABLE 227
TRIBUN HEALTH: DEALS, JANUARY 2021–APRIL 2025
TABLE 228
TECHCYTE, INC.: COMPANY OVERVIEW
TABLE 229
TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
TABLE 230
TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 231
TECHCYTE, INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 232
TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 233
DEEP BIO INC.: COMPANY OVERVIEW
TABLE 234
DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
TABLE 235
DEEP BIO INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 236
LUMEA INC.: COMPANY OVERVIEW
TABLE 237
LUMEA INC.: PRODUCTS/SERVICES OFFERED
TABLE 238
LUMEA INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 239
VISIOPHARM: COMPANY OVERVIEW
TABLE 240
VISIOPHARM: PRODUCTS/SERVICES OFFERED
TABLE 241
VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 242
VISIOPHARM: EXPANSIONS, JANUARY 2021– APRIL 2025
TABLE 243
AETHERAI: COMPANY OVERVIEW
TABLE 244
AETHERAI: PRODUCTS/SERVICES OFFERED
TABLE 245
AETHERAI: DEALS, JANUARY 2021– APRIL 2025
TABLE 246
AIOSYN: COMPANY OVERVIEW
TABLE 247
AIOSYN: PRODUCTS/SERVICES OFFERED
TABLE 248
AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 249
AIOSYN: DEALS, JANUARY 2021–APRIL 2025
TABLE 250
AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 251
PAIGE AI, INC.: COMPANY OVERVIEW
TABLE 252
PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
TABLE 253
PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021– APRIL 2025
TABLE 254
PAIGE AI, INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 255
PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 256
PROSCIA, INC.: COMPANY OVERVIEW
TABLE 257
PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 258
PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 259
PROSCIA, INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 260
PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 261
PATHAI, INC.: COMPANY OVERVIEW
TABLE 262
PATHAI, INC.: PRODUCTS/SERVICES OFFERED
TABLE 263
PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 264
PATHAI, INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 265
TEMPUS LABS, INC.: COMPANY OVERVIEW
TABLE 266
TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 267
TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 268
KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
TABLE 269
DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
TABLE 270
QRITIVE: COMPANY OVERVIEW
TABLE 271
DEEPPATH: COMPANY OVERVIEW
TABLE 272
4D PATH INC.: COMPANY OVERVIEW
FIGURE 2
KEY PRIMARY SOURCES
FIGURE 3
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4
MARKET SIZE ESTIMATION PROCESS
FIGURE 5
KEY INSIGHTS FROM INDUSTRY EXPERTS
FIGURE 6
BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY
FIGURE 7
AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030)
FIGURE 8
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 9
TOP-DOWN APPROACH
FIGURE 10
DATA TRIANGULATION METHODOLOGY
FIGURE 11
AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
FIGURE 12
AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION)
FIGURE 13
AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION)
FIGURE 14
AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 15
AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 16
DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET
FIGURE 17
NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 18
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024
FIGURE 19
INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 20
AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21
HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
FIGURE 22
TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 23
ECOSYSTEM ANALYSIS
FIGURE 24
VALUE CHAIN ANALYSIS
FIGURE 25
EUROPE: IVDR TIMELINE
FIGURE 26
PORTER’S FIVE FORCES
FIGURE 27
NUMBER OF PATENTS PUBLISHED, JANUARY 2017−APRIL 2025
FIGURE 28
NUMBER OF PATENT DOCUMENTS, BY JURISDICTION
FIGURE 29
TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2017–APRIL 2025
FIGURE 30
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 31
KEY BUYING CRITERIA, BY END USER
FIGURE 32
FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
FIGURE 33
MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
FIGURE 34
IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD)
FIGURE 35
EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD THOUSAND)
FIGURE 36
NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
FIGURE 37
ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
FIGURE 38
REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION)
FIGURE 39
AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024)
FIGURE 40
AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 41
AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
FIGURE 42
AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 43
EV/EBITDA OF KEY VENDORS
FIGURE 44
YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN PATHOLOGY VENDORS
FIGURE 45
BRAND/PRODUCT COMPARISON
FIGURE 46
KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)
FIGURE 47
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
FIGURE 48
HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
FIGURE 49
AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 50
AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
FIGURE 51
TEMPUS: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in AI in Pathology Market